Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

CDE Reference Standards 101st Batch Seeks Public Feedback

Fineline Cube Dec 23, 2025
Company Drug

Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer

Fineline Cube Dec 23, 2025
Company Drug

Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval

Fineline Cube Dec 23, 2025
Company Drug

Jiangsu Hengrui Pharmaceutials’ SHR-1209 for Hypercholesterolemia Accepted for NMPA Review

Fineline Cube Jun 21, 2023

China-based Jiangsu Hengrui Pharmaceutials (SHA: 600276) has announced that a market filing for its Category...

Company Drug

Minghui Pharmaceutical Achieves First Dosing Milestone in Phase I Studies for ADC Candidates

Fineline Cube Jun 21, 2023

China-based biotech Minghui Pharmaceutical Inc. has reported that the first dosing has been completed in...

Company Deals

Xiamen ITG Group and Fosun Health Collaborate on Big Health Industry Fund and Medical Device Commercialization

Fineline Cube Jun 21, 2023

China-based Xiamen ITG Group Co., Ltd. (SHA: 600755) and Shanghai Fosun Health Technology (Group) Co.,...

Company Medical Device

Australian Scleral Lens Epicon A Approved by China’s NMPA as 10th Novel Product

Fineline Cube Jun 21, 2023

Ruitai Bio’s Epicon A, a scleral lens product from Australia, has been approved by the...

Company Drug

CDE Considers Breakthrough Therapy Designation for Beijing Mabworks’ MIL162 and Amgen’s AMG 890

Fineline Cube Jun 21, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Beijing Mabworks Biotech Co., Ltd’s...

Company Drug

Fujian Cosunter Pharmaceutical’s COVID-19 Drug GST-HG171 Meets Primary Endpoint in Phase II/III Study

Fineline Cube Jun 21, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that the pivotal Phase II/III...

Company Drug

Boehringer Ingelheim’s Spevigo on Track for Priority Review for GPP Flare Prevention in China

Fineline Cube Jun 21, 2023

Germany-based Boehringer Ingelheim’s (BI) interleukin-36 receptor (IL-36R)-targeted orphan drug, Spevigo (spesolimab), in subcutaneous injection form,...

Company Drug

Bio-Thera Solutions’ PD-1 Inhibitor BAT1308 Approved for Cervical Cancer Clinical Trials in China

Fineline Cube Jun 21, 2023

Bio-Thera Solutions Ltd (SHA: 688177) has announced that its programmed death-1 (PD-1) inhibitor, BAT1308, has...

Company

Pfizer to Establish Smart Medical Innovation Center in Hangzhou’s Qiantang District

Fineline Cube Jun 20, 2023

US pharmaceutical giant Pfizer (NSE: PFIZER) has announced a plan to establish a smart medical...

Company Legal / IP

Medivir AB Receives Chinese Patent Approval for Liver Cancer Treatment Fostroxacitabine Bralpamide

Fineline Cube Jun 20, 2023

Sweden-based Medivir AB (FRA: MVR0) has announced the approval of a patent in China for...

Company Deals

Shanghai Cell Therapy Group Partners with Nantong Federation for Comprehensive Health Services Platform

Fineline Cube Jun 20, 2023

Shanghai Cell Therapy Group has entered into a partnership with the Nantong Federation of Industry...

Company Deals

Huadong Medicine’s Subsidiary Perfect mRNA Biotechnology Partners with Yoltech Therapeutics

Fineline Cube Jun 20, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) subsidiary, Hangzhou Perfect mRNA Biotechnology Co., Ltd, has...

Company

Merck Appoints Marc Horn as China Unit President, Succeeding Allan Gabor

Fineline Cube Jun 20, 2023

Germany-based Merck (NYSE: MRK) has announced the appointment of Marc Horn as its China unit...

Company Drug

Sinocelltech Group Launches Biosimilar Version of AbbVie’s Humira in China

Fineline Cube Jun 20, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has officially commercialized its biosimilar version of AbbVie’s (NYSE:...

Company Drug

Grand Pharmaceutical Initiates Phase II STARBURST Study for TLX250-CDx in Indication Expansion

Fineline Cube Jun 20, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...

Company Deals

Novlead Biotech Secures RMB 100 Million in Series B+ Financing for Nitric Oxide Therapy Innovations

Fineline Cube Jun 20, 2023

Novlead Biotech, a specialist in nitric oxide gas detection and treatment based in Nanjing, has...

Company Deals

Guangdong Zhongsheng Pharmaceutical Plans to Raise RMB 600 Million via Private Placement

Fineline Cube Jun 20, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) is poised to raise RMB 600 million...

Company Drug

Shanghai Pharmaceuticals’ SPH3127 for Hypertension Gets MNPA Review Acceptance

Fineline Cube Jun 20, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products...

Company Deals

United Imaging Healthcare Acquires Stake in Apactron for High-End Particle Therapy Technology

Fineline Cube Jun 20, 2023

Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has announced an investment of RMB 45 million...

Company Deals

Sequanta Technologies Partners with DarkJade Sciences to Establish Organoid Bank and Glioma Project

Fineline Cube Jun 20, 2023

Sequanta Technologies, a leading multi-omics research and clinical service provider based in Shanghai, has announced...

Posts pagination

1 … 447 448 449 … 601

Recent updates

  • Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer
  • CDE Reference Standards 101st Batch Seeks Public Feedback
  • Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval
  • J&J TREMFYA Pediatric Psoriasis EC Approval Targets First IL-23 Indication
  • Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer

Policy / Regulatory

CDE Reference Standards 101st Batch Seeks Public Feedback

Company Drug

Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval

Company Drug

J&J TREMFYA Pediatric Psoriasis EC Approval Targets First IL-23 Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.